The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), and th...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society for the Study of Obesity
2019-03-01
|
Series: | Journal of Obesity & Metabolic Syndrome |
Subjects: | |
Online Access: | https://doi.org/10.7570/jomes.2019.28.1.18 |